NantHealth (NYSE: NH) is one of 20 publicly-traded companies in the “Medical Software & Technology Services” industry, but how does it contrast to its peers? We will compare NantHealth to similar companies based on the strength of its earnings, analyst recommendations, institutional ownership, dividends, risk, profitability and valuation.
This table compares NantHealth and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of recent ratings and price targets for NantHealth and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
NantHealth presently has a consensus price target of $9.25, indicating a potential upside of 172.06%. As a group, “Medical Software & Technology Services” companies have a potential upside of 20.82%. Given NantHealth’s stronger consensus rating and higher possible upside, equities research analysts plainly believe NantHealth is more favorable than its peers.
Valuation & Earnings
This table compares NantHealth and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|NantHealth Competitors||$422.43 million||-$16.79 million||394.12|
NantHealth’s peers have higher revenue, but lower earnings than NantHealth. NantHealth is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
60.4% of shares of all “Medical Software & Technology Services” companies are owned by institutional investors. 26.7% of shares of all “Medical Software & Technology Services” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
NantHealth peers beat NantHealth on 7 of the 10 factors compared.
NantHealth Company Profile
NantHealth, Inc. is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples. The Company also offers Nant Operating System (NantOS) and NantOS applications to healthcare providers and payors, self-insured employers and biopharmaceutical companies. It offers CLINICS, an integrated solution that includes GPS Cancer, NantOS and the NantOS applications. The CLINICS solution includes System Infrastructure, Knowledge Platform, Provider Platform and Payor Platform.
Receive News & Ratings for NantHealth Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth Inc and related companies with MarketBeat.com's FREE daily email newsletter.